Esperion's cholesterol drug safe, effective in new late-stage study [Reuters]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Reuters
Esperion's cholesterol drug safe, effective in new late-stage study | Reuters Reuters Staff 1 Min Read May 23 (Reuters) - Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment’s efficacy. Esperion’s shares plunged some 30 percent on May 2 after analysts questioned the drug’s safety and effectiveness despite late-stage results showing that the treatment had met the main study goal. In the new study, the treatment, bempedoic acid, met the main goal of reduction in low-density lipoprotein cholesterol levels when compared with a placebo. The study results also showed that adverse muscle-related side effects were lower in patients taking Esperion’s treatment compared with those on a placebo. Esperion’s shares rose nearly 3 percent in premarket trading. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in Upcoming May Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in Upcoming May Investor ConferencesGlobeNewswire
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7GlobeNewswire
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 4/11/24 - Form DEF
- 4/11/24 - Form ARS
- 3/15/24 - Form 4
- ESPR's page on the SEC website